Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View INTI insider activity ↗

INTIInhibitor Therapeutics, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$3.3M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$0Year ended December 31, 2021
Profit or loss-$3.3MYear ended December 31, 2025
Cash from the business-$3.23MYear ended December 31, 2025
Total assets$637.19KAs of June 30, 2026
Total liabilities$3.2MAs of June 30, 2026
Cash & equivalents$515.76KAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$0
2014-12
$0
2015-12
$0
2016-12
$0
2017-12
$0
2018-12
$0
2019-12
$0
2020-12
$0
2021-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2021 – December 31, 2021$0March 30, 202210-K ↗
January 1, 2020 – December 31, 2020$0March 30, 202210-K ↗
January 1, 2019 – December 31, 2019$0March 26, 202110-K ↗
January 1, 2018 – December 31, 2018$0March 7, 201910-K ↗
January 1, 2017 – December 31, 2017$0March 7, 201910-K ↗
January 1, 2016 – December 31, 2016$0February 16, 201810-K ↗
January 1, 2015 – December 31, 2015$0February 17, 201710-K ↗
January 1, 2014 – December 31, 2014$0February 1, 201610-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 12, 2026

Response SHA-256: 4142a89736990e49cb86be8cc08735b878648c52aa079c470055b2d7cd387cb7

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.